China's NMPA Approves Merck’s Keytruda Plus Chemotherapy as Neoadjuvant Treatment of NSCLC
Shots:
- The NMPA has approved Keytruda + Pt-CT as neoadj. treatment, followed by monotx. as adjuvant treatment for resectable NSCLC (stage II, IIIA, or IIIB) based on P-III (KEYNOTE-671)
- This study assessed EFS & OS as 1EP for Keytruda + CT as neoadjuvant, followed by surgery & Keytruda alone as an adjuvant vs PBO + CT to treat NSCLC patients (n=797)
- Study depicted improvement in OS with a 28% reduction in the death risk & mOS not achieved vs 52.4mos. as well as improvement in EFS with a 42% reduction in the disease recurrence, progression or death risk
Ref: Merck | Image: Merck
Related News:- Merck Reports the CHMP’s Positive Opinion of Welireg (Belzutifan) for Von Hippel-Lindau (VHL) Disease-Associated Tumors and Previously Treated Renal Cell Carcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
